Lipoxygenase-derived metabolites are regulators of peroxisome proliferator-activated receptor γ-2 expression in human vascular smooth muscle cells

American Journal of Hypertension

Volumn 21, Issue 2, 2008, Pages 219-223

  Limor, Rona ^a,b   Sharon, Orly ^a,b   Knoll, Esther ^a,b   Many, Ariel ^a,b   Weisinger, Gary ^a,b   Stern, Naftali ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

13 HYDROXYOCTADECADIENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; CELL NUCLEUS RECEPTOR; LIPOXYGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; ROSIGLITAZONE; STEARIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; CELLS, CULTURED; GENE EXPRESSION; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; HYPOGLYCEMIC AGENTS; MUSCLE, SMOOTH, VASCULAR; PPAR GAMMA; RNA, MESSENGER; THIAZOLIDINEDIONES; UMBILICAL CORD; UP-REGULATION;

EID: 38949189651     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2007.39     Document Type: Article

References (35)

1. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007; 115:518-33.
2. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR-γ-2, a lipid-activated transcription factor. Cell 1994; 79:1147-1156.
3. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliever SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 1995; 270:12953-12956.
4. Willson TM, Cobb JE, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglygemic activity of thiazolidinediones. J Med Chem 1996; 39:665-668.
5. Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM. PPAR-γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93:241-252.
6. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391:79-82.
7. Jiang C, Tiang AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokine. Nature 1998; 391:82-86.
8. Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPAR-δ decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 2001; 98:2598-2603.
9. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. Terminal differentiation of human breast cancer through PPAR-γ. Mol Cell 1998; 1:465-470.
10. Kliewer SA. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Sci USA 1997; 94:4318-4323.
11. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995; 83:813-819.
12. 2 is a ligand for adipocyte determination factor PPAR-γ. Cell 1995; 83:803-812.
13. His LC, Wilson L, Nixon J, Eling TE. 15-Lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor γ via the MAPK signaling pathway. J Biol Chem 2001; 276:34545-34662.
14. Pham H, Banejee T, Nalbandian G, Ziboh VA. Activation of peroxisome proliferator-activated receptors (PPAR)-γ by 15S-hydroxyeicosatrienoic acid parallels growth suppression of androgen-dependent prostatic adenocarcinoma cells. Cancer Lett 2003; 189:17-25.
15. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structure, biosynthesis and biological effects. Science 1987; 237:1171-1176.
16. Steinberg D, Parthasarathy S, Carew TE, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenity. N Engl J Med 1989; 320:915-924.
17. Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC, Kelloff GJ. Potential use of lipoxygenase inhibitors for cancer chemoprevention. Expert Opin Invest Drugs 2000; 9:2121-2138.
18. Dwarakanath RS, Sahar S, Reddy MA, Castanotto D, Rossi JJ, Natarajan R. Regulation of monocyte chemoattractant protein-1 by the oxidized lipid, 13-hydroperoxyoctadecadienoic acid, in vascular smooth muscle cells via nuclear factor-κ B (NF-κ B). J Mol Cell Cardiol 2004; 36:585-595.
19. Limor R, Weisinger G, Gilad S, Knoll E, Sharon E, Jaffe A, Kohen F, Berger E, Lifshizt-Mercer B, Stern N. A novel form of platelet-type 12-lipoxygenase mRNA in human vascular smooth muscle cells. Hypertension 2001; 38:864-871.
20. Limor R, Kaplan M, Sawamura T, Sharon O, Knead S, Weisinger G, Knoll E, Naidich M, Stern N. Angiotensin II increases the expression of lectin-like oxidized low-density lipoprotein receptor-1 in human vascular smooth muscle cells via a lipoxygenase-dependent pathway. Amer J Hypertens 2005; 18:299-307.
21. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, Reddy JK. Structural organization of mouse peroxisome proliferator-activated receptor γ gene alternative promoter use and different splicing yield two mPPAR γ isoforms. Proc Natl Acad Sci 1995; 92:7021-7025.
22. Fajas L, Fruchart JC and Auwerx J. PPAR-γ3 mRNA: a distinct PPAR-γ mRNA subtype transcribed from an independent promoter. FEBS Lett 1998; 438:55-60.
23. Inoue G, Kuzuya H, Hayashi T, Okamoto M, Yoshimasa Y, Kosaki A, Kono S, Okamoto M, Maeda I, Kubota M, Imura H. Effects of ML-9 on insulin stimulation of glucose transport in 3-T3-L1 adipocytes. J Biol Chem 1993; 268:5272-5278.
24. Eskra JD, Pereira MJ, Ernest MJ. Solid-phase extraction and high-performance liquid chromatography analysis of lipoxygenase pathway products. Anal Biochem 1986; 154:323-337.
25. Benkirane K, Amiri F, Diep QN, El Mabrouk M, Schiffrin EL. PPAR-γ inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 2006; 290:H390-H397.
26. Gao DF, Niu XL, Hao GH, Peng N, Wei J, Ning N, Wang NP. Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-γ in vascular fibrosis. Biochem Pharmacol 2007; 73:185-197.
27. Ogawa D, Nomiyama T, Nakamachi T, Heywood EB, Stone JF, Berger JP, Law RE, Bruemmer D. Activation of peroxisome proliferator-activated receptor gamma suppresses telomerase activity in vascular smooth muscle cells. Circ Res 2006; 98:e50-e59.
28. Lim S, Jin CJ, Kim M, Chung SS, Park HS, Lee IK, Lee CT, Cho YM, Lee HK, Park KS. PPARγ gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. Arterioscler Thromb Vasc Biol 2006; 26:808-813.
29. Redondo S, Ruiz E, Santos-Gallego CG, Padilla E, Tejerina T. Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-γ, transforming growth factor-β1, and a Smad2-dependent mechanism. Diabetes 2005; 54:811-817.
30. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, Case T, Price J, Jack GS, Wheeler TM, Matusik RJ, Brash AR, Dubois RN. 15S-hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001; 61:497-503.
31. Pham H, Banerjee T, Nalbandian GM, Ziboh VA. Activation of peroxisome proliferator-activated receptor (PPAR)-γ by 15S-hydroxyeicosatrienoic acid parallels growth suppression of androgen-dependent prostatic adenocarcinoma cells. Cancer Lett 2003; 189:17-25.
32. Ricote M, Welch JS, Glass CK. Regulation of macrophage gene expression by the peroxisome proliferator-activated receptor-γ. Horm Res 2000; 54:275-280.
33. Tang DG, Chen YQ, Honn KV. Arachdonate lipoxygenase as essential regulators f cell survival and apoptosis. Proc Natl Acad Sci USA 1996; 93:5241-5246.
34. Weisinger G, Hirsh M, Knoll E, Stern N. Platelet-type 12S-lipoxygenase antisense knockout or biochemical inhibition induces programmed cell death in human vascular smooth muscle cells. Am J Hypertens 2004; 17(Suppl):S8 (abstract).
35. Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. Oncogene 2006; 25:6015-6025.